Alterations of gyrA, gyrB, and parC and Activity of Efflux Pump in Fluoroquinolone-resistant Acinetobacter baumannii

Osong Public Health and Research Perspectives

Volumn 2, Issue 3, 2011, Pages 164-170

  Park, Sunok ^a   Lee, Kyeong Min ^a   Yoo, Yong Sun ^a   Yoo, Jung Sik ^a   Yoo, Jae Il ^a   Kim, Hwa Su ^a   Lee, Yeong Seon ^a   Chung, Gyung Tae ^a  

^a Korea National Institute of Health   (South Korea)

Author keywords

A baumannii; Efflux pump fluoroquinolone resistance; GyrA; GyrB; ParC

Indexed keywords

ALANINE; ASPARTIC ACID; BACTERIAL PROTEIN; CIPROFLOXACIN; EFFLUX PUMP; GATIFLOXACIN; GEMIFLOXACIN; GLUTAMIC ACID; LEUCINE; LEVOFLOXACIN; LYSINE; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; VALINE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BROTH DILUTION; EPSILOMETER TEST; GENE MUTATION; GENE SEQUENCE; GYRA GENE; GYRB GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARC GENE; PRIORITY JOURNAL;

EID: 84855200908     PISSN: 22109099     EISSN: 22109110     Source Type: Journal    
DOI: 10.1016/j.phrp.2011.11.040     Document Type: Article

References (25)

1. Perez F., Hujer A.M., Hujer K.M., et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007 Oct, 51(10):3471-3484.
2. Valentine S.C., Contreras D., Tan S., et al. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J Clin Microbiol 2008 Aug, 46(8):2499-2507.
3. Spence R.P., Towner K.J. Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother 2003 Oct, 52(4):687-690.
4. Vila J., Ruiz J., Goñi P., Marcos A. Jimenez de Anta T. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 1995 May, 39(5):1201-1203.
5. Vila J., Ruiz J., Goñi P., Jimenez de Anta T. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother 1997 Jun, 39(6):757-762.
6. Hamouda A., Amyes S.G.B. Novel gyrA and parC point mutations in two strains of Acinetobacter baumannii resistant to ciprofloxacin. J Antimicrob Chemother 2004 Sep, 54(3):695-696.
7. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003 May, 51(5):1109-1117.
8. Higgins P.G., Wisplinghoff H., Stefanik D., Seifert H. Selection of topoisomerase mutaitons and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J Antimicrob Chemother 2004 Oct, 54(4):821-823.
9. Vila J., Ribera A., Marco F., et al. Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2002 Mar, 49(3):471-477.
10. Seral C., Barcia-Macay M., Mingeot-Leclercq M.P., et al. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. J Antimicrob Chemother 2005 Apr, 55(4):511-517.
11. Noble C.G., Maxwell A. The role of GyrB in the DNA cleavage-religation reaction of DNA Gyrase: a proposed two metal-ion mechanism. J Mol Biol 2002 Apr 26, 318(2):361-371.
12. Heddle J., Maxwell A. Quinolone-binding pocket of DNA gyrase: role of GyrB. Antimicrob Agents Chemother 2002 Jun, 46(6):1805-1815.
13. Lee K., Chang C.L., Lee N.Y., et al. Korean Nationwide Surveillance of Antimicriobial Resistance of Bacteria in 1998. Yonsei Med J 2000 Aug, 41(4):497-506.
14. Yong D., Cheong H.J., Kim Y.S., et al. In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea. J Koran Med Sci 2002 Dec, 17(6):737-742.
15. Clinical and Laboratory Standards Institute (CLSI) 2007 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard - 7th ed., M100-S20. Wayne, PA: CLSI.
16. Pumbwe L., Chang A., Smith R.L., Wexler H.M. Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates. J Antimicrob Chemother 2006 Sep, 58(3):543-548.
17. Thompson J.D., Higgins D.G., Gibson T.J. Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acids Res 1994 Nov 11, 22(22):4673-4680.
18. Nakamura S., Nakamura M., Kojima T., Yoshida H. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob Agents Chemother 1989 Feb, 33(2):254-255.
19. Lee J.K., Lee Y.S., Park Y.K., Kim B.S. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2005 Apr, 25(4):290-295.
20. Lina L., Linga B.D., Li X.Z. Distribution of the multidrug efflux pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii -Acinetobacter calcoaceticus complex. Int J Antimicrob Agents 2009 Jan, 33(1):27-32.
21. Coyne S., Rosenfeld N., Lambert T., et al. Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2010 Oct, 54(10):4389-4393.
22. Aeschlimann J.R. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other Gram-negative bacteria. Pharmacotherapy 2003 Jul, 23(7):916-924.
23. Poole K. Efflux-mediated resistance to fluorquinolones in gram-negative bacteria. Antimicrob Agents Chemother 2000 Sep, 44(9):2233-2241.
24. Bratu S., Landman D., Martin D.A., et al. Correlation of antimicrobial resistance with β-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. Antimicrob. Agents Chemother 2008 Sep, 52(9):2999-3005.
25. Pannek S., Higgins P.G., Steinke P., et al. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-b-naphthylamide. J Antimicrob Chemother 2006 May, 57(5):970-974.